NHSX

Quantexa Appoints Industry Luminaries to its Advisory Board to Accelerate Growth Plans

Retrieved on: 
Friday, September 22, 2023
National Cyber Security Centre (United Kingdom), Advisory board, MI5, Health, BlackRock, Intelligence, NHSX, Government, GCHQ, Organization, COVID-19, Growth, AI, NHS, GIC, Management, Renewable energy

LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Quantexa, the global leader in Decision Intelligence (DI) solutions for the private and public sectors, announced today that it has appointed three industry luminaries to its Advisory Board.

Key Points: 
  • LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Quantexa, the global leader in Decision Intelligence (DI) solutions for the private and public sectors, announced today that it has appointed three industry luminaries to its Advisory Board.
  • These distinguished leaders bring a wealth of expertise in finance, healthcare, and national security to Quantexa.
  • Ralph Schlosstein, former CEO of Evercore and former President of BlackRock, brings decades of experience in investment banking to Quantexa’s Advisory Board.
  • "We are pleased to welcome Ralph Schlosstein, Matthew Gould, and Sir Jeremy Fleming to our Advisory Board," said Vishal Marria, CEO of Quantexa.

UK National Screening Committee Report Singles Out Eyenuk’s EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health Service

Retrieved on: 
Wednesday, June 1, 2022
CPT, PDF, Doctor of Philosophy, NIH, Diabetes, Technology, UK National Screening Committee, Food and Drug Administration, Moorfields Eye Hospital, HIPAA, Severe cognitive impairment, GDPR, Stroke, Moorfields Eye Hospital NHS Foundation Trust, Food, CEO, CE, NHS, Solution, Health Canada, Diagnosis, Population, Diabetic retinopathy, United Kingdom, Risk assessment, AI, Government, Organization, Patient, NSC, NHSX, Eye, Population health, American Diabetes Association, LinkedIn, Glaucoma, National Health Service (England), Intelligence, General Data Protection Regulation, FDA, GLOBE, Risk, Health Insurance Portability and Accountability Act, DESP, Union, Twitter, Accountability Act, National Health Service, Safety, Medical device, Pharmaceutical industry, Facebook

The 169-page NSC report identified the EyeArt v2.1 algorithm for autonomous diabetic retinopathy screening as the only AI technology ready for live clinical implementation in the UK.

Key Points: 
  • The 169-page NSC report identified the EyeArt v2.1 algorithm for autonomous diabetic retinopathy screening as the only AI technology ready for live clinical implementation in the UK.
  • The UK has been leading the world in diabetic retinopathy screening, achieving patient uptake rates of over 80% (screening nearly 2.5 million diabetes patients annually).
  • Eyenuk will showcase the EyeArt AI System during the American Diabetes Associations 82nd Scientific Sessions in New Orleans, June 3-7.
  • The EyeArt AI System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS).

Huma calls for safeguarding of scientific collaboration to tackle global health challenges during event at World Economic Forum

Retrieved on: 
Wednesday, May 18, 2022
Diabetes, Global Innovation through Science and Technology initiative, Hospital, Knowledge, University, COVID-19, Degenerative disease, Alzheimer's disease, Atrial fibrillation, Coronavirus, Environment, Multilateralism, Patient, Vaccine, Solution, Health, Therapy, World Economic Forum, Clinical trial, Dr. Jeyasekharan Hospital & Nursing Home, Mumps, Mortality, Thought, Technology, Research, Global health, Software, Home, Partnership, Vahdat, Gaps, NHSX, Head, Infection, LinkedIn, Movement, Founder, Huma, Cancer, Medical device, AstraZeneca, Pharmaceutical industry

COVID-19 showed that rapid scientific advances can be achieved through global collaboration across disciplines, geographies and sectors.

Key Points: 
  • COVID-19 showed that rapid scientific advances can be achieved through global collaboration across disciplines, geographies and sectors.
  • "COVID-19 exposed the glaring inequalities in global health, the gaps in our knowledge and the faults in our systems.
  • "The World Economic Forum provides leading start-ups like Huma a platform to help tackle important problems such as providing more resilient, efficient, and equitable healthcare systems," said Verena Kuhn, Head, Global Innovators Community at the World Economic Forum.
  • "Scientific collaboration is vital in finding such healthcare solutions and Huma can provide important insights into how digital can be better leveraged in public-private health care collaboration."

Huma calls for safeguarding of scientific collaboration to tackle global health challenges during event at World Economic Forum

Retrieved on: 
Wednesday, May 18, 2022
Diabetes, Global Innovation through Science and Technology initiative, Hospital, Knowledge, University, COVID-19, Degenerative disease, Alzheimer's disease, Atrial fibrillation, Coronavirus, Environment, Multilateralism, Patient, Vaccine, Solution, Health, Therapy, World Economic Forum, Clinical trial, Dr. Jeyasekharan Hospital & Nursing Home, Mumps, Mortality, Thought, Technology, Research, Global health, Software, Home, Partnership, Vahdat, Gaps, NHSX, Head, Infection, LinkedIn, Movement, Founder, Huma, Cancer, Medical device, AstraZeneca, Pharmaceutical industry

COVID-19 showed that rapid scientific advances can be achieved through global collaboration across disciplines, geographies and sectors.

Key Points: 
  • COVID-19 showed that rapid scientific advances can be achieved through global collaboration across disciplines, geographies and sectors.
  • "COVID-19 exposed the glaring inequalities in global health, the gaps in our knowledge and the faults in our systems.
  • "The World Economic Forum provides leading start-ups like Huma a platform to help tackle important problems such as providing more resilient, efficient, and equitable healthcare systems," said Verena Kuhn, Head, Global Innovators Community at the World Economic Forum.
  • "Scientific collaboration is vital in finding such healthcare solutions and Huma can provide important insights into how digital can be better leveraged in public-private health care collaboration."

Huma and Tamer bring digital 'hospital at home' platform to the Kingdom of Saudi Arabia to tackle diabetes and cardiovascular disease

Retrieved on: 
Tuesday, May 17, 2022
Diabetes, MHealth, Death, Medicine, BD, Patient, Health, Dialysis, Therapy, CVD, COVID-19, Marketing, Cardiovascular disease, Research, Partnership, Jonathan Obika, Hospital, Technology, NHSX, Attention, Group, LinkedIn, Founder, JAMIA, Glycated hemoglobin, CEO, Health insurance, Pharmaceutical industry, Medical device, Kingdom

The new health programme will begin with support for patients with diabetes and cardiovascular disease.

Key Points: 
  • The new health programme will begin with support for patients with diabetes and cardiovascular disease.
  • Cardiovascular disease (CVD) and diabetes are the biggest cause of premature death in the Kingdom of Saudi Arabia.
  • Patients will now be able to use Huma's award-winning3 'hospital at home' system to give clinicians real-world insightinto their patients' health.
  • Dr Fayad Dandashi, CEO Tamer Healthcare, said: "Tamer is delighted to be able to offer this leading technology.

Huma and Tamer bring digital 'hospital at home' platform to the Kingdom of Saudi Arabia to tackle diabetes and cardiovascular disease

Retrieved on: 
Monday, May 16, 2022
Diabetes, MHealth, Death, Medicine, BD, Patient, Health, Dialysis, Therapy, CVD, COVID-19, Marketing, Cardiovascular disease, Research, Partnership, Jonathan Obika, Hospital, Technology, NHSX, Attention, Group, LinkedIn, Founder, JAMIA, Glycated hemoglobin, CEO, Health insurance, Pharmaceutical industry, Medical device, Kingdom

The new health programme will begin with support for patients with diabetes and cardiovascular disease.

Key Points: 
  • The new health programme will begin with support for patients with diabetes and cardiovascular disease.
  • Cardiovascular disease (CVD) and diabetes are the biggest cause of premature death in the Kingdom of Saudi Arabia.
  • Patients will now be able to use Huma's award-winning3 'hospital at home' system to give clinicians real-world insightinto their patients' health.
  • Dr Fayad Dandashi, CEO Tamer Healthcare, said: "Tamer is delighted to be able to offer this leading technology.

Huma wins 'best of the best' Prix Galien International 2022 award

Retrieved on: 
Friday, May 13, 2022
Diabetes, COVID-19, NEW, AI, Medicine, Bill, Coronavirus, Hypoxia, Patient, Health, Therapy, Johns Hopkins, Nobel Prize, Research, Software, Partnership, 100 Tourist Sites of Bulgaria, Hospital, Technology, NHSX, LinkedIn, Massachusetts General Hospital, Natural History Museum, Bill & Melinda Gates Foundation, Huma, Stanford University, Medtronic, Medical device, AstraZeneca, CEO, Pharmaceutical industry

LONDON and NEW YORK, May 13, 2022 /PRNewswire/ -- Huma Therapeutics has won the highly coveted Prix Galien International 2022 'best of the best digital health product' award for the impact of its remote patient monitoring platform across healthcare and research.

Key Points: 
  • LONDON and NEW YORK, May 13, 2022 /PRNewswire/ -- Huma Therapeutics has won the highly coveted Prix Galien International 2022 'best of the best digital health product' award for the impact of its remote patient monitoring platform across healthcare and research.
  • Prix Galien International, considered 'the Nobel Prize for life sciences', compares winners from the previous three years and is judged by some of the world's most eminent experts.
  • Huma recently announced its plans to accelerate digital-first patient care and research in the US with a partnership with AstraZeneca.
  • The Prix Galien International Award for best digital product had joint winners, with congratulations going to Medtronic for their automatic insulin pump.

Huma wins 'best of the best' Prix Galien International 2022 award

Retrieved on: 
Friday, May 13, 2022
Diabetes, COVID-19, NEW, AI, Medicine, Bill, Coronavirus, Hypoxia, Patient, Health, Therapy, Johns Hopkins, Nobel Prize, Research, Software, Partnership, 100 Tourist Sites of Bulgaria, Hospital, Technology, NHSX, LinkedIn, Massachusetts General Hospital, Natural History Museum, Bill & Melinda Gates Foundation, Huma, Stanford University, Medtronic, Medical device, AstraZeneca, CEO, Pharmaceutical industry

LONDON and NEW YORK, May 13, 2022 /PRNewswire/ -- Huma Therapeutics has won the highly coveted Prix Galien International 2022 'best of the best digital health product' award for the impact of its remote patient monitoring platform across healthcare and research.

Key Points: 
  • LONDON and NEW YORK, May 13, 2022 /PRNewswire/ -- Huma Therapeutics has won the highly coveted Prix Galien International 2022 'best of the best digital health product' award for the impact of its remote patient monitoring platform across healthcare and research.
  • Prix Galien International, considered 'the Nobel Prize for life sciences', compares winners from the previous three years and is judged by some of the world's most eminent experts.
  • Huma recently announced its plans to accelerate digital-first patient care and research in the US with a partnership with AstraZeneca.
  • The Prix Galien International Award for best digital product had joint winners, with congratulations going to Medtronic for their automatic insulin pump.

The Galien Foundation Hosts First-Ever Prix Galien UK Forum Celebrating Life Science Innovation

Retrieved on: 
Thursday, April 14, 2022
Natural History Museum, CEO, Medicine, Science Museum, Science, World Cultural Council 30th Award Ceremony, Bill & Melinda Gates Foundation, Paganini Competition, Research, Health, Health policy, NHSX, Biopharmaceutical, Driver, Organization, 100 Tourist Sites of Bulgaria, Award, EVP, Nobel Prize, Mene, Technology, Social media, Vaccine, United Kingdom, Imperial College London, Foundation, Bill, AstraZeneca, Public health, Awards ceremony, COVID, Pharmaceutical industry, Tutoring, Public relations

LONDON, April 14, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced it will host the first Prix Galien Forum in the United Kingdom on Thursday, 12 May at the Science Museum, London. Panel discussions will focus on topical issues at the country level to highlight cutting-edge global research collaborations, local policies and business practices that support the development of innovative medicines, vaccines and other high-value health technologies, from devices to digital.

Key Points: 
  • The Prix Galien Forum UK schedule is as follows.
  • Additionally, The Galien Foundation will introduce a new award category during the Awards Ceremony, the Prix Galien Lifetime Achievement Award.
  • Sue Desmond-Hellmann, Chair of the Prix Galien USA and Prix Galien International Awards Committees and former CEO of the Bill & Melinda Gates Foundation.
  • The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology.

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

Retrieved on: 
Wednesday, March 23, 2022
Adoption, Drug development, Therapy, LinkedIn, Conditional sentence, NEW, Diagnosis, Medical device, Gaps, Health, Physician, Research, Hospital, CEO, Chief digital officer, AstraZeneca, Software, NHSX, American Academy of Family Physicians, Industry, Technology, Goal, Foundation, American Academy, Samding Dorje Phagmo, Science, Family medicine, Patient, Partnership, Pharmaceutical industry

As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate adoption of decentralized clinical trials.

Key Points: 
  • As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate adoption of decentralized clinical trials.
  • These will build on Huma's proven technologies which already power digital-first care serving more than 1.8 million active patient users across more than 3,000 hospitals and clinics.
  • AstraZeneca has invested in the development and clinical validation of the patient centered AMAZE chronic disease management platform to improve the care of patients.
  • The collaboration with Huma will leverage the strong foundations and early success of AMAZETM to accelerate digital-first care across therapeutic areas and launch SaMDs.